Effects of Specialized Strength Training Protocol On Functional Movement Status of Office Workers

May 19, 2024 updated by: Riphah International University
The aim of the study was to determine the effects of specialized strength training protocol on the functional movement status of office workers, and to assess and evaluate the quality of movement patterns and identify any limitations that may exist in order to prevent musculoskeletal injuries, using Functional movement screening. Randomized controlled trials done at Codistan Ventures and Zakori Industries Private Limited. The sample size was 100. The subjects were divided in two groups, 50 subjects in Specialized Strength Training Protocol group and 50 in 30 minute walk group. Study duration was of 6 months. Sampling technique applied was non probability connivance sampling technique. Only 20-35 years office desk workers with no known musculoskeletal deformity were included. Tool used in the study was Functional Movement Screening Test.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

As the world is becoming more corporate, the increase in number of hours a person spends in his or her workplace has certainly shifted people towards a sedentary way of life. Sitting and working for a long time in an improper position leads to the tightness and weakness of the muscles, which can lead to musculoskeletal disorders such as neck, shoulders, and lower back pains as well as anatomical disorders such as lordosis, kyphosis, and scoliosis.Most causes of these symptoms include long sitting and excessive leaning. Individuals with areas of muscular weaknesses cannot perform fundamental movement patterns due to compensatory adaptations which can increase the risk of injury. To combat workplace-caused mental and physical exhaustion physical activity has been proven to be an efficient tactic. Physical activity is known not to only treat but prevent the occurrence of a fore coming disease. Being physically active will lead to reduced stress levels and increased productivity. According to World Health Organization facts physical activity refers to all movement including during leisure time, for transport to get to and from places, or as part of a person's work. Both moderate- and vigorous-intensity physical activity improve health that also includes walking for 150-300 minutes a week for adults. Some physical activity is better than doing none. By becoming more active throughout the day in relatively simple ways, people can easily achieve the recommended activity levels.Physical Fitness is defined as the ability to perform physical activity and comprises of components such as flexibility, strength and endurance. A complete physical fitness regimen must target core and extremities. A strong musculoskeletal system is recognized as important component of health related physical fitness. Strength training program provides an opportunity to improve health, physical fitness and quality of life. Core strengthening involving multiplane movements has plausible benefits to improve functional movement patterns. Combination of core strengthening along with upper and lower extremities strengthening program is needed to improve the physical fitness in active individuals to improve their functional status. The topic of FMS (Functional Movement Status) development has received considerable interest owing to the close association between health and well-being, physical activity, and to a lesser degree physical performance.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
100

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Pakistan
    • KPK
      • Peshawar, KPK, Pakistan
        • Care Cloud and Zakori Industries Limited

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Both gender

  • Office Workers whose age lies between 15 and 30
  • Both male and female gender
  • At least 6-8 hours shift per day
  • Job duration >6 months
  • FMS ≤14

Exclusion Criteria:

reviously diagnosed Musculoskeletal disorder or injury

  • Cardiovascular disorders
  • Rheumatoid arthritis
  • Acute infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental interventional group A
Exercises for core, gluts, upper body and lower body
Other: Exercises
Experimental Group Exercises for Core: Crunches, Glute bridges Crunches Glute bridge Week 1-2 (set/rep/sec) Week 3-4 (set/rep/sec) Week 5-6 (set/rep/sec) Exercises for upper body: Push up (4), Bicep curls Exercises Weeks Reps/sets Push up walk out Bicep curls 1-3 16-20*3 Push up Bicep curl with Dumbbell 4-6 12-15*3 Exercises for Lower body: Lunges and Squats Exercises Weeks Reps/set Split Squat with body weight Body weight Squat 1-3 16-20*3 Split Squat with Dumbbell Squat with Dumbbell 4-6 12-15*
Active Comparator: Control group B
Walking for 30 min 5 days a week
Other: Walking
Walking for 30min, 5 days a week

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Functional Movement screening Questionnaire (FMS)
Time Frame: Baseline to 6th week
FMS is a composite performance measure that is also an injury predictor. it consists of seven basic functional patterns: deep squat, hurdle step, in-line lunge, shoulder mobility, active straight leg raises, trunk stability push-up and rotary stability. each test will be give a score of 3 if performane correct, 2 if performed with compensation, 1 if unable to perform the pattern, 0 if there is pain associated with it. max. score will be 21 and if score is less than 14 that means that person is prone to injury in future.
Baseline to 6th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Riphah International University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Aisha Razzaq, MSPT-OMPT, Riphah International University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 20, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
January 30, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 15, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 26, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 5, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 6, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 21, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 19, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
May 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RiphahIU Lubna Ali

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings